
|
|
|
|
|
|
|
|
The present technology has several
unique advantages compared to conventional alternatives to replace torn
ACL but also other ligaments and tendons. Firstly, the approach allows
permanent implantation of the ACL substitute while synthetic prosthesis
such as dacron or lad are susceptible to wear off particules in the knee
joint within a few years, leading to inflammatory reactions, cartilage
degeneration and funtional instability of the knee. Secondly, the
bioengineered ACL doesn't present any risk of graft rejection since we
intend to use autologous ACL cells from the hosts, their own bone
fragments and eventually recombinant Type I collagen. Thirdly, this
technology avoids taking any portion of healthy autologous tissues, such
as a part of the patellar, semitendinous or semimembranous tendons for
ACL replacement , which often lead to chronic pain, muscular weakness or
instability of the knee joint. Therefore, any conventional approach would
still be feasible in case of bACL failure. Also, the autologous ACL cells
could be conserved in a cell depository to prepare another bACL for the
patients who would break the graft under traumatic circumstances. Lastly,
the procedure of implantation could be performed by arthroscopy, avoiding
arthrotomies and associated risks (infection, knee pain, loss of
articular mobility, major swelling and permanent scar). |
|
|
|
|
Human and animal (e.g. horse, dog) ACL of the knee joint Other ligaments, tendons, disks, meniscus Dentistry (ligament) Cell / gene therapy
Repair, notably the ACL: in response to:
Organization and remodeling |
|
|
|
|
Goat implantation over 1 year: showed
that the autologous implant is integrated, reinforced, remodeled and not
rejected
|
|
![]() The first goat grafted with our ACL substitute, 1 month post-surgery. |
U.S.A. patents 09/990,320 and 10/678,167